Credit: Illustration: Patrick Bibbins, Children's Hospital Boston
Toll-like receptors (TLRs) on the surface of white blood cells provide a first line of defense against infection. But in newborns, most of them respond poorly -- except for TLR8. Levy and colleagues believe that agents that stimulate TLR8 could be given as vaccine adjuvants to enhance newborns' immune responses.